Lyra Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Lyra Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2019 to 2023.
  • Lyra Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $8.64M, a 116% increase year-over-year.
  • Lyra Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $65.7M, a 31.8% decline from 2022.
  • Lyra Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $96.3M, a 26713% increase from 2021.
  • Lyra Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $359K, a 99.6% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $65.7M -$30.6M -31.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-22
2022 $96.3M +$95.9M +26713% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-22
2021 $359K -$87.3M -99.6% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-29
2020 $87.7M +$87.8M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-09
2019 -$115K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.